Evidence map›Paper›PMID 25939819›Full record

ArticleThe British journal of radiology2015

Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.

X-X Li, N-B Liu, L Zhu, X-K Yuan, C-W Yang, P Ren, L-L Gong, L-J Zhao, W-G Xu, P Wang

Open access · hybridAbstract read
In one paragraph

Article in The British journal of radiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Diagnostic accuracy of dual-phaseScientific reports · 2025
    Article
  3. Review
  4. Pancreatic cancer in 2021: What you need to know to win.World journal of gastroenterology · 2021
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

X-X Li1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
N-B Liu1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
L Zhu2 Department of Molecular Imaging and Nuclear Medicine, Department of Radiation Oncology and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
X-K Yuan3 Department of Radiotherapy, Heibei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, Cangzhou, China.
C-W Yang1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
P Ren4 Department of Esophagus Carcinoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
L-L Gong1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
L-J Zhao1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
W-G Xu2 Department of Molecular Imaging and Nuclear Medicine, Department of Radiation Oncology and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
P Wang1 Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Tianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the differences between contrast-enhanced (CE) fluorine-18 fludeoxyglucose ((18)F-FDG) positron emission tomography (PET)/CT and CECT in target volume delineation and radiotherapy (RT) dose distribution, and to evaluate the sparing of organs at risk (OARs) in the treatment plan of locally advanced pancreatic cancer (LAPC).

methods21 consecutive patients with LAPC with histologically or cytologically confirmed adenocarcinoma underwent both non-CECT and (18)F-FDG scans; 11 of whom also underwent CECT scans. Intensity-modulated RT plans (prescribed dose, 54 Gy) were constructed to cover the corresponding gross tumour volume (GTV). The differences among GTVCT, GTVPET, GTVPET-CT and OARs in these different image sets as well as the uniformity of target dose were analysed.

resultsThe mean non-CE GTVCT, GTVPET and GTVPET-CT were 76.9 ± 47.8, 47.0 ± 40.2 and 44.5 ± 34.7 cm(3) (mean ± standard deviation), respectively. The non-CE GTVPET-CT was significantly smaller than the non-CE GTVCT (p < 0.001). The CE GTVPET-CT was significantly smaller than the CE GTVCT (p = 0.033). For both the non-CE GTVCT and the CE GTVCT, the intestine V40 (the percentage of the intestine volume irradiated by 40 Gy), intestine V50, intestine Dmax (the mean maximum dose), cord Dmax, left kidney V30, right kidney V30, left kidney Dmean (the mean dose), right kidney Dmean and liver V30 were 5.90%, 2.52%, 5500 cGy, 2194 cGy, 3.40%, 0.68%, 747 cGy, 550 cGy and 5.37%, respectively. There are significant differences between the non-CE CT and the non-CE PET-CT in intestine Dmax (p = 0.023) and right kidney Dmean (p = 0.029).

conclusionCo-registration of (18)F-FDG PET with CECT may improve the accuracy of GTV delineation in LAPC and might reduce the adverse effect of irradiation. ADVANCES IN KNOWLEDGE: Individual adaptation of RT based on functional CE (18)F-FDG PET/CT imaging is possible and highly promising in LAPC.

Indexed as

Fluorodeoxyglucose F18RadiopharmaceuticalsAdenocarcinomaAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm InvasivenessOrgans at RiskPancreatic NeoplasmsPeritoneal NeoplasmsPositron-Emission TomographyRadiotherapy DosageRadiotherapy Planning, Computer-AssistedFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID25939819
PMCPMC4628516
OpenAlexW1911223844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.